Dalteparin sodium - VTE treatment in patients unable to take oral anticoagulants

You are here : Home > Formulary Search > Dalteparin sodium - VTE treatment in patients unable to take oral anticoagulants

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue

Formulations :

Subcutaneous injection (sc)

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

BNF SPC

Restrictions / Comments :

Important

Excluding obstetric and cancer patients. Specialist initiation and at least one month supply before transfer to primary care.

Documentation

Evidence Review

Low Molecular Weight Heparins (LMWH) for Venous Thromboembolism (VTE) - Colour change Dec19.pdf

PAD Profile

ChemicalSubstance :

Dalteparin sodium

Indication :

VTE treatment in patients unable to take oral anticoagulants

Group Name :

Keywords :

Venous Thromboembolism, Low molecular weight heparins, LMWH

Brand Names Include :

Fragmin

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Dalteparin sodium is used to treat.

Other Drugs

Below are listed other drugs that are used to treat VTE treatment in patients unable to take oral anticoagulants.

Committee Recommendations (1)

04 Dec 19 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Area Prescribing Committee recommends the use of low weight molecular heparins (LWMH) for the treatment of VTE in those patients who are unable to take oral anticoagulants (excluding obstetric patients and those on current cancer chemotherapy).

LMWH will be considered BLUE (no information sheet) on the traffic light system for the above indications (see below for exclusions).

The specialist should prescribe the initial 1st month of drug treatment. Primary care can take over prescribing upon receipt of an agreed treatment plan from the specialist, which must include details of drug dosage, possible side-effects, and action to take if problems arise, as per local guidance.

LMWH will be considered RED for obstetric use and in patients on current cancer chemotherapy.

Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication